CO6180427A2 - Tratamiento de los trastornos generalizados del desarrollo - Google Patents
Tratamiento de los trastornos generalizados del desarrolloInfo
- Publication number
- CO6180427A2 CO6180427A2 CO09056106A CO09056106A CO6180427A2 CO 6180427 A2 CO6180427 A2 CO 6180427A2 CO 09056106 A CO09056106 A CO 09056106A CO 09056106 A CO09056106 A CO 09056106A CO 6180427 A2 CO6180427 A2 CO 6180427A2
- Authority
- CO
- Colombia
- Prior art keywords
- substituted
- alkyl
- disorder
- pdd
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
1.- Un método de tratamiento de los trastornos generalizados del desarrollo (PDD's) que incluyen: trastorno autista, trastorno de Asperger, trastorno desintegrativo de la niñez (CDD), trastorno de Rett, y PDD's no especificados de otra manera (PDD-NOS), que comprende administrar a un sujeto en necesidad del mismo una cantidad terapéuticamente efectiva de un compuesto de fórmula 1 o de fórmula 2:o una forma de sal o éster farmacéuticamente aceptable del mismo, en donde: R1, R2, R3 y R4 son independientemente hidrógeno o alquilo de C1-C4, en donde el alquilo de C1-C4 no está sustituido o está sustituido con fenilo, y en donde el fenilo no está sustituido o está sustituido con hasta cinco sustituyentes seleccionados independientemente de halógeno, alquilo de C1-C4, alcoxi de C1-C4, nitro, ciano y amino, en donde el amino opcionalmente está mono- o disustituido con alquilo de C1-C4, y X1, X2, X3, X4 y X5 son independientemente hidrógeno, flúor, cloro, bromo, o yodo. 2.- El método que se reclama en la reivindicación 1, en donde X es un sustituyente cloro en la posición orto del anillo de fenilo, y en donde R1, R2, R3, R4, R5 y R6 se seleccionan de hidrógeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86359506P | 2006-10-31 | 2006-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6180427A2 true CO6180427A2 (es) | 2010-07-19 |
Family
ID=39145417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09056106A CO6180427A2 (es) | 2006-10-31 | 2009-06-01 | Tratamiento de los trastornos generalizados del desarrollo |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20080103199A1 (es) |
| EP (1) | EP2089011A1 (es) |
| JP (1) | JP2010508354A (es) |
| KR (1) | KR20090080105A (es) |
| CN (1) | CN101568333A (es) |
| AU (1) | AU2007313911A1 (es) |
| BR (1) | BRPI0718323A2 (es) |
| CA (1) | CA2667909A1 (es) |
| CO (1) | CO6180427A2 (es) |
| EA (1) | EA200970435A1 (es) |
| GT (1) | GT200900112A (es) |
| IL (1) | IL198488A0 (es) |
| MX (1) | MX2009004798A (es) |
| NI (1) | NI200900074A (es) |
| NO (1) | NO20092019L (es) |
| WO (1) | WO2008054984A1 (es) |
| ZA (1) | ZA200903772B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7702468B2 (en) | 2006-05-03 | 2010-04-20 | Population Diagnostics, Inc. | Evaluating genetic disorders |
| US10522240B2 (en) | 2006-05-03 | 2019-12-31 | Population Bio, Inc. | Evaluating genetic disorders |
| WO2010020585A1 (en) * | 2008-08-18 | 2010-02-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Serotonin reuptake inhibitors for the treatment of rett syndrome |
| DK2601609T3 (en) | 2010-08-02 | 2017-06-06 | Population Bio Inc | COMPOSITIONS AND METHODS FOR DISCOVERING MUTATIONS CAUSING GENETIC DISORDERS |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| DK2766483T3 (da) | 2011-10-10 | 2022-04-19 | Hospital For Sick Children | Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser |
| WO2013067451A2 (en) | 2011-11-04 | 2013-05-10 | Population Diagnostics Inc. | Methods and compositions for diagnosing, prognosing, and treating neurological conditions |
| CA2863887C (en) | 2012-02-09 | 2023-01-03 | Population Diagnostics, Inc. | Methods of screening low frequency gdna variation biomarkers for pervasive developmental disorder (pdd) or pervasive developmental disorder - not otherwise specified (pdd_nos) |
| AU2013299725A1 (en) * | 2012-08-06 | 2015-03-26 | S1 Biopharma, Inc. | Treatment regimens |
| DK2895621T3 (da) | 2012-09-14 | 2020-11-30 | Population Bio Inc | Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande |
| CA2922005A1 (en) | 2012-09-27 | 2014-04-03 | Population Diagnostics, Inc. | Methods and compositions for screening and treating developmental disorders |
| KR101717871B1 (ko) * | 2013-03-12 | 2017-03-20 | (주)바이오팜솔루션즈 | 페닐카바메이트 화합물 및 이를 포함하는 기억 손실-관련 질환의 예방 또는 치료용 조성물 |
| WO2016036403A1 (en) | 2014-09-05 | 2016-03-10 | Population Diagnostics Inc. | Methods and compositions for inhibiting and treating neurological conditions |
| WO2018111008A1 (ko) * | 2016-12-14 | 2018-06-21 | 에스케이바이오팜 주식회사 | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| US10240205B2 (en) | 2017-02-03 | 2019-03-26 | Population Bio, Inc. | Methods for assessing risk of developing a viral disease using a genetic test |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| SI3625368T1 (sl) | 2018-08-08 | 2023-04-28 | Pml Screening, Llc | Postopki z genetskim testiranjem za oceno tveganja za razvoj progresivne multifokalne levkoencefalopatije, ki jo povzroča virus John Cunningham |
| CN114206349A (zh) | 2019-04-17 | 2022-03-18 | 指南针探路者有限公司 | 治疗神经认知障碍、慢性疼痛及减轻炎症的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1262271C (zh) * | 2001-02-27 | 2006-07-05 | 奥索-麦克尼尔药品公司 | 用于预防或治疗精神病的氨基甲酸酯化合物 |
| RU2300372C2 (ru) * | 2001-02-27 | 2007-06-10 | Орто-Макнейл Фармасьютикал, Инк. | Карбаматы для применения для предотвращения или лечения биполярного расстройства |
| WO2002067925A1 (en) * | 2001-02-27 | 2002-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| KR100858232B1 (ko) * | 2001-02-27 | 2008-09-12 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 카바메이트 화합물을 포함하는 거동 장애 예방 또는 치료용 약제학적 조성물 |
| EA200700642A1 (ru) * | 2004-09-16 | 2007-10-26 | Янссен Фармацевтика, Н. В. | Способы лечения эпилептогенеза и эпилепсии |
-
2007
- 2007-10-15 CN CNA2007800482055A patent/CN101568333A/zh active Pending
- 2007-10-15 WO PCT/US2007/081365 patent/WO2008054984A1/en active Application Filing
- 2007-10-15 AU AU2007313911A patent/AU2007313911A1/en not_active Abandoned
- 2007-10-15 MX MX2009004798A patent/MX2009004798A/es not_active Application Discontinuation
- 2007-10-15 US US11/872,177 patent/US20080103199A1/en not_active Abandoned
- 2007-10-15 EA EA200970435A patent/EA200970435A1/ru unknown
- 2007-10-15 JP JP2009535384A patent/JP2010508354A/ja not_active Withdrawn
- 2007-10-15 KR KR1020097011061A patent/KR20090080105A/ko not_active Application Discontinuation
- 2007-10-15 EP EP07844287A patent/EP2089011A1/en not_active Withdrawn
- 2007-10-15 CA CA002667909A patent/CA2667909A1/en not_active Abandoned
- 2007-10-15 BR BRPI0718323-2A patent/BRPI0718323A2/pt not_active Application Discontinuation
-
2009
- 2009-04-30 GT GT200900112A patent/GT200900112A/es unknown
- 2009-04-30 IL IL198488A patent/IL198488A0/en unknown
- 2009-04-30 NI NI200900074A patent/NI200900074A/es unknown
- 2009-05-25 NO NO20092019A patent/NO20092019L/no not_active Application Discontinuation
- 2009-05-29 ZA ZA200903772A patent/ZA200903772B/xx unknown
- 2009-06-01 CO CO09056106A patent/CO6180427A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101568333A (zh) | 2009-10-28 |
| IL198488A0 (en) | 2010-02-17 |
| US20080103199A1 (en) | 2008-05-01 |
| WO2008054984A1 (en) | 2008-05-08 |
| JP2010508354A (ja) | 2010-03-18 |
| KR20090080105A (ko) | 2009-07-23 |
| ZA200903772B (en) | 2010-08-25 |
| CA2667909A1 (en) | 2008-05-08 |
| EP2089011A1 (en) | 2009-08-19 |
| GT200900112A (es) | 2010-05-18 |
| EA200970435A1 (ru) | 2009-10-30 |
| AU2007313911A1 (en) | 2008-05-08 |
| BRPI0718323A2 (pt) | 2013-11-26 |
| NO20092019L (no) | 2009-06-23 |
| MX2009004798A (es) | 2009-08-12 |
| NI200900074A (es) | 2010-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6180427A2 (es) | Tratamiento de los trastornos generalizados del desarrollo | |
| ECSP088179A (es) | Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos | |
| NO20071921L (no) | Fremgangsmater for behandling av epileptogenese og epilepsi | |
| AR054524A1 (es) | Metodos y formas de dosificacion para reducir los efectos secundarios de compuestos de carbamato | |
| CL2011002990A1 (es) | Compuestos derivados de bifenilo, inhibidores de endopeptidasa neutra (nep); composición farmacéutica; combinación farmacéutica; uso del compuesto para tratar un trastorno o enfermedad tal como la hipertensión, insuficiencia cardiaca, insuficiencia renal, glaucoma, trastornos reproductivos, entre otros. | |
| ECSP088172A (es) | Metodos para tratar la epileptogenesis | |
| CO6300945A2 (es) | Compuestos fenil ftalazin - 1l piperidin - 4 - il benzamida o sales farmaceuticamente aceptables de los mismos, utiles como antagonistas de la trayectoria hedgehoc (hh) | |
| CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
| AR052885A1 (es) | Metodos para el control del intervalo qt | |
| EA200800422A1 (ru) | Способы лечения заболеваний, обусловленных химическими веществами | |
| AR083180A1 (es) | Amidas de oxopiperazina-azetidina y amidas oxodiazepina-azetidina como inhibidores de monoacilglicerol lipasa | |
| NI200700094A (es) | Métodos para la neuroprotección | |
| CO6180505A2 (es) | Metodos para el tratamiento de transtornos cocleares y vestibulares | |
| CO6160292A2 (es) | Metodos de tratamiento de transtornos de comportamiento perturbador 877 | |
| AR077884A1 (es) | (4-(5-aminometil- fenil)-piperidin-1-il)-1h-indol-3-il)-metanonas disustituidas | |
| AR058230A1 (es) | Derivados de pirilsulfonamida y composicion farmaceutica | |
| ECSP088237A (es) | Derivados de quinolina y uso como agentes antitumor | |
| PE20040943A1 (es) | 2-AMINOIMIDAZOLES SUSTITUIDOS COMO INHIBIDORES DEL INTERCAMBIADOR Na/H SUBTIPO 3 (NHE 3) | |
| UY29158A1 (es) | Metodos de tratamiento de la epileptogénesis y la epilepsia | |
| AR035757A1 (es) | Uso de carbamatos para la fabricacion de medicamentos para prevenir o tratar un trastorno bipolar | |
| AR079292A1 (es) | Inhibidores de replicacion del virus de la hepatitis c | |
| AR034785A1 (es) | Compuestos de carbamato para utilizarse en la prevencion o tratamiento de dolor neuropatico y dolor asociado con cefalea migranosa y cefalea acuminada | |
| CY1110672T1 (el) | Χρηση των 2- φαινυλ-1,2-αιθανοδιολης- (δι) καρβαμικων για θεραπεια επιληπτογενεσης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |